7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow Constellation Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies Pelabresib - Advanced Malignancies, Solid Tumor | Phase 1 | Completed | Constellation Pharmaceuticals | 35 | 2021-07-20 | 2025-07-28 |
| ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors CPI-1205, ipilimumab - Advanced Solid Tumors | Phase 1 | Completed | Constellation Pharmaceuticals | 24 | 2017-12-14 | 2022-05-18 |
| ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer CPI-1205, Cobicistat, Enzalutamide - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 175 | 2017-11-15 | 2025-10-29 |
| A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas CPI-1205 - B-Cell Lymphoma | Phase 1 | Completed | Constellation Pharmaceuticals | 41 | 2015-03-01 | 2022-05-18 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma CPI-0610 - Multiple Myeloma | Phase 1 | Completed | Constellation Pharmaceuticals | 30 | 2014-07-15 | 2024-04-18 |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma CPI-0610 - Lymphoma | Phase 1 | Completed | Constellation Pharmaceuticals | 64 | 2013-09-05 | 2024-05-08 |
Neoplasms (5) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms by Histologic Type (1) · Precancerous Conditions (1) · Preleukemia (1)
(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (3) · CPI-0610 (3) · Cobicistat (1) · Ipilimumab (1) · Prednisone (1) · abiraterone (1) · enzalutamide (1) · ruxolitinib (1)
United States (5) · Belgium (1) · Canada (1) · France (1) · Georgia (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
PMID 36881782, PMID 36923307, PMID 37530627, PMID 38259250
2018 (1)